2 Hrs
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
2 Hrsالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
2 HrsReady to play
Ready to play
The U.S. Food and Drug Administration is investigating reports of tumors in children treated with Zolgensma for spinal muscular atrophy. The company has received nine reports among more than 6,000 patients who have received the drug. Tumors were reported in the central and peripheral nervous systems, the spine, and the kidneys; in two cases, DNA from the virus used in the treatment was detected in the tumors. The agency is monitoring the risks and assessing whether regulatory action is needed, but said that the treatment’s benefits continue to outweigh its potential risks.
Notice: This Is an AI-Generated Summary
Comments (0)